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Summary: A solid phase sandwich immunoenzymmetric assay is described for the determination of apolipo-
protein B in apolipoprotein CII- and/or CHI-containing lipoproteins (chylomicron remnants, VLDL, IDL).
During a first incubation step the particles containing apolipoproteins CII and/or CIII are bound to antibodies
against these components, while the antibodies are immobilised on microtitre plate wells. After washing, anti-
apolipoprotein B is added in a second incubation step. Finally peroxidase-labelled anti-sheep IgG reacts with
the bound anti-apolipoprotein B, thus allowing the quantification of complexes containing both B and CII/
CIII apolipoproteins.
The amounts of these complexes were correlated with total cholesterol, triacylglycerols, HDL- and LDL-
cholesterol, apolipoproteins AI and B, as well as with age and sex of the subject. A total of 258 individuals
was studied, including patients with lipid metabolism disorders, patients with manifest coronary heart disease,
and healthy controls.
The assay described in this article was compared with radial immunodiffusion after pretreatment of samples.
The immunoenzymmetric assay was easier and faster to perform and had a lower detection limit than the
classical VLDL apolipoprotein B determination using ultracentrifugation. Furthermore, it could be performed
directly on native serum.
Most importantly, the study revealed elevated apolipoprotein CII/CIII-B levels in coronary heart disease
patients of both sexes compared with normal subjects. Furthermore, in male coronary heart disease patients
a negative correlation was found between the concentrations of apolipoprotein CII/CIII-B and HDL-
cholesterol. These results suggest a delayed VLDL-HDL exchange of lipids and proteins in these patients
which results in an accumulation of atherogenic apolipoprotein B-containing VLDL and IDL.
Introduction 1 1 - n · .1 · . ,*~ „^chylomicrons as well as in their remnants (12 — 16).
The total serum concentration of apolipoprotein B is Although an increase in VLDL concentration does
a well known risk factor for premature coronary heart not appear to represent a primary risk factor for
disease. LDL enriched in apolipoprotein B relative to coronary heart disease, some studies have revealed an
lipids are known to be especially atherogenic (1 — 11). association between increased concentrations of this
However, in hypertriglyceridaemic sera, up to 50% lipoprotein and premature development of athero-
of total apolipoprotein B are present in VLDL and sclerosis (17 — 19). The special role played by VLDL
in the development of atherosclerosis may lie in the
') Funding organisation: Ministerium für Wissenschaft, For- altered composition of these particles in patients when
schung und Technik Nordrhein-Westfalen, IV B 5-40001986 compared with healthy controls (20, 21). Hence it is
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of interest to quantify the concentration of apolipo-
protein B in VLDL. To date, the measurement of this
analyte requires time-consuming analysis with ultra-
centrifugation or lengthy sample preparation (22, 23).
Due to these obstacles, epidemiological or larger clin-
ical studies have not taken this important quantity
into consideration.
We present here an immunoenzymmetric quantitation
of apolipoprotein CII/CIH-apolipoprotein B which
can be performed within one working day, without
ultracentrifugation and pretreatment of samples. Fur-
thermore, native lipoprotein particles are used, which
eliminates disturbances due to artificial changes. This
technique is based on the fact that VLDL are the only
lipoproteins in human serum which contain C apoli-
poproteins as well as apolipoprotein B, with the ex-
ception of relatively small amounts of chylomicron
remnants and IDL. In a first step, all apolipoprotein
CII/CHI-containig lipoproteins are linked to the fixed
phase. In the second step, the apolipoprotein B con-
tained in these particles is quantified.
Materials and Methods
Samples
In this study we investigated a total of 258 subjects who be-
longed to the following groups:
(a) normal individuals: 90 male and 31 female subjects of the
PROCAM study pool (24) showing normal lipid and lipoprotein
patterns, and fasting glucose concentrations within the normal
range (3.33 — 6.05 mmol/1)
(b) patients with coronary heart disease: 61 male and 18 female
patients of the LVA Fachklinik Salzetal (Head: Prof. Dr. E.
K hler) with coronary atherosclerosis as confirmed by coronary
angiography
(c) subjects with lipid metabolism disorders: 35 male and 23
female patients from the outpatient clinic of the Institute of
Clinical Chemistry and Laboratory Medicine, University of
M nster, presenting with various forms of dyslipidaemia.
Measurements were done on large series of frozen serum sam-
ples, which were frozen at —70 °C for a maximum of 6 months.
Stability of the samples for at least 6 months had been ascer-
tained previously in a comparative study of 30 samples.
Methods
Raising of ant ibodies and preparation for assay
Apolipoproteins CII and CIII were isolated by preparative
isoelectric focusing of VLDL apolipoproteins, which were ob-
tained by ultracentrifugation and subsequent delipidation (25).
Anti-apolipoprotein CII and anti-apolipoprotein CIII antisera
were raised in two New Zealand white rabbits by subcutaneous
injection of l mg of the respective antigen in complete Freuntfs
adjuvant, followed after six weeks with a booster injection of
a 0.5 mg apolipoprotein in incomplete Freund*s adjuvant. Start-
ing at the third week after boosting, 40ml blood was taken
from the auricular artery once a week from each rabbit. The
antisera were tested for monospecifity by Ouchterlony diffusion,
two-dimensional electroimmunodiffusion, and Western blotting
against isolated lipoproteins as well as purified apolipoproteins.
In the immunoenzymmetric assay a mixture of equal amounts
of chromatographically (DEAE-sepharose) purified IgG frac-
tions (26) of anti-apolipoprotein CII and anti-apolipoprotein
CIII antibodies was used for coating. For the detection step,
sheep anti-apolipoprotein B antibodies (Boehringer Mannheim)
and horseradish peroxidase-labelled anti-sheep IgG (Dako)
were used. The anti-apolipoprotein C antibodies were stored at
—20 °C, anti-apolipoprotein B antibodies and the enzyme con-
jugate at + 4 °C.
Lipid analysis
Total cholesterol and triacylglycerols were determined enzy-
matically with the SMAC autoanalyser (Technicon GmbH) as
previously described (27). HDL-cholesterol was measured fol-
lowing precipitation with phosphotungstic acid/MgC!2 (28) us-
ing the COBAS Bio centrifugal analyser (Roche). LDL-choles-
terol was calculated using the Friedewald formula (29).
Apol ipoprote in analysis
Apolipoproteins AI and B were measured turbidimetrically, as
previously described (30). For the determination of apolipo-
protein CII/CIH-apolipoprotein B, microtitre plates from Dy-
natech were selected, because specific binding of antibodies
during coating was high and unspecific binding during the
following incubation steps was low, compared with other mi-
crotitre plates (Costar, Flow, NUNC). No interlot variations
were observed using three different lots of Dynatech plates.
The microtitre plates were coated with the optimal concentra-
tion of 0.1 μg anti-apolipoprotein CII +0.1 μg anti-apolipo-
protein CIII per well, which had been determined earlier in a
dilution series using a checker board system. Coating was
performed overnight in carbonate buffer (0.1 mol/1, pH 9.6),
followed by washing 5 times with 0.15 mmol/1 NaCl containing
50 μΐ/ΐ Tween 20. A sample (100 μΐ) containing serum and
phosphate buffered saline (0.1 mol/1, pH 7.4) in a ratio 1 : 100
or 1 :200 was placed in each well of the microtitre plate and
incubated for two hours. After washing 5 times with phosphate
buffered saline, 1 μg anti-apolipoprotein B antibody (Boehrin-
ger Mannheim), diluted 1 : 20000 in phosphate buffered saline
was added to each well and incubated for two hours. Subse-
quently the plates were again washed 5 times with phosphate
buffered saline and then incubated for two hours with peroxi-
dase-labelled anti-sheep antibody diluted 1 : 1000 in phosphate
buffered saline. All incubation steps were carried out at room
temperature. After another washing step, 100 μΐ o-phenylene-
diamine/H2O2 were added as substrate. The colour reaction was
stopped after half an hour by addition of 100 μΐ 1 mol/1 H2SO4.
A Dynatech MR 600 microtitre reader coupled to a computer
was used for data reduction.
Intra- and inter-assay variation
The intra-assay variations amounted to 7.5% and 5.5%
(n = 20) and the inter-assay variations were 10.4% and 6.7%
(n = 30) at concentrations of 0.08 g/1 and 0.16 g/1 apolipopro-
tein CII/CIII-B, respectively. The linear range extended from
0.01 g/1 to 0.5 g/1. The sensitivity of the assay was 10 μg/l
apolipoprotein CII/CIII-B. Disturbances by extremely high
concentrations of triacylglycerols (> 6.8 mmol/1) or cholesterol
(> 10.4 mmol/1) were not observed.
Calibration
The assays were calibrated with a dilution series of a normo-
lipaemic pool serum. After determination of total apolipopro-
tein B using turbidimetry, all CII/CIII-containing lipoproteins
were removed by antibody-mediated fixed phase immune ad-
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Tab. l. Distribution of age and lipid quantities in normal subjects
Males (n = 90)
mean median S.D.
* significantly different when compared with female subjects, p < 0.05


























































Sorption on nylon membranes (Nalgene). Subsequently apoli-
poprotein B was remeasured in the remainder. The amount of
apolipoprotein CII/CIII-B was calculated from the difference
between this latter value and the total apolipoprotein B value.
Statistical analysis
For the statistical evaluation of the data the "Statistical Package
for the Social Sciences" (SPSS*) was used (31). The Mann-
Whitney U-test was applied for a comparison of parameter
distribution in different collectives. The parameter independent
Spearman-test was used for the calculations of correlations
whithin the different subgroups, the Kruskal-Wallis-Test for
comparing more than two groups. For all calculations the level
of significance was p < 0.05.
Tab. 2. Normal subjects: Spearman correlation coefficients be-


























Distributions and and correlations
Control group
Table 1 describes mean values, median, and standard
deviations of the lipid, lipoprotein, and apolipopro-
tein values measured in the normal collective.
Table 2 describes univariate correlations between apo-
lipoprotein CII/CIII-B concentration and age, con-
centrations of total cholesterol, triacylglycerols,
HDL-cholesterol, LDL-cholesterol, apolipoprotein
AI, and apolipoprotein B. In both men and women
apolipoprotein CII/CIII-B positively correlated with
age, concentrations of total cholesterol, LDL-choles-
terol, and apolipoprotein B. Additionally a positive
correlation was found between apolipoprotein CII/
CIII-B and triacylglycerols in men. Furthermore, a
significantly negative correlation was shown between
apolipoprotein CII/CIII-B and apolipoprotein AI
concentration in women.
Coronary patients
The distribution of lipid quantities measured in the
collective of male and female patients with coronary
heart disease is shown in table 3. In male patients
































































significantly different when compared with female subjects, p < 0.05
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apolipoprotein CII/CIII-B negatively correlated with
HDL-cholesterol and positively with cholesterol, tria-
cylglycerols, LDL-cholesterol, and apolipoprotein B.
In female patients, only a correlation between apoli-
poprotein CII/CIII-B and age was found (tab. 4).
Tab. 4. Coronary heart disease patients: Spearman correlation
coefficients between age, apolipoprotein CII/CIII-B,























* p < 0.05
Dyslipidaemic patients
In table 5 the statistical description of a group of
dyslipidaemic patients is presented. In men we ob-
served a negative correlation between apolipoprotein
CII/CIII-B and age, in women a positive correlation
between apolipoprotein CII/CIII-B and the concen-
trations of cholesterol, triacylglycerols, LDL-choles-
terol, and apolipoprotein B (tab. 6).
Comparison of groups
Table 7 shows a comparison of the results obtained
in the 3 different male collectives. Of special interest
are the significantly lower HDL-cholesterol and apo-
lipoprotein AI concentrations in the group of coro-
nary heart disease patients compared with the control
group and the group of hyperlipidaemic patients. Fur-
thermore, the coronary heart disease patients group
Tab. 6. Hyperlipidaemic subjects: Spearman correlation coef-

























Tab. 7. Group-dependent differences in males
(group 1: hyperlipidaemic subjects, group 2: normal
subjects, group 3: coronary heart disease patients)
Group 1 Group 2 Group 3


































* significantly different between group 1 and group 2,
p < 0.05
** significantly different between group 1 and group 3,
p < 0.05
*** significantly different between group 2 and group 3,
p < 0.05
presents with significantly higher concentrations of
apolipoprotein CII/CIII-B than the other two groups.
Also in the female coronary heart disease patients,
HDL-cholesterol and apolipoprotein AI are lower
and apolipoprotein CII/CIII-B concentrations are
higher, but only in comparison with the normal fe-
males (tab. 8).

































































significantly different when compared with female subjects, p < 0.05
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Tab. 8. Group-dependent differences in females
(group 1: hyperlipidaemic subjects, group 2: normal








































* significantly different between group 1 and group 2,
p < 0.05
** significantly different between group 1 and group 3,
p < 0.05
*** significantly different between group 2 and group 2,
p < 0.05
Discussion
Methods previously available for the quantitation of
apolipoprotein B in different lipoproteins were disad-
vantageous, because their laborious sample prepara-
tion, precipitation, or ultracentrifugation precluded
their use for the investigation of large numbers of
samples. The immunoenzymmetric assay introduced
here allows for the quantitation of apolipoprotein B
in native particles from serum and permits the eco-
nomic study of larger collectives. Furthermore, meas-
urements with the immunoenzymmetric assay result
in faster and more accurate results than the radial
immunodiffusion method, which has been described
for the determination of VLDL apolipoprotein B (32).
Another important advantage of this new method is
that the measured analyte is defined much more ac-
curately by its apolipoprotein composition than li-
poproteins obtained by ultracentrifugation or precip-
itation with polyanions.
Calibration is difficult for both radial immunodiffu-
sion and immunoenzymmetric assays. Radial immu-
nodiffusion is calibrated with an apolipoprotein B
value obtained by determination of tetramethyl urea-
insoluble proteins in the supernatant after polyvinyl-
sulphate precipitation (32). This procedure requires
several steps and therefore easily leads to inaccuracies.
The calibration of the immunoenzymmetric assay test
only requires the immunoadsorption, and no further
preparative or dilution procedures.
It is important to note that the analytes, VLDL apo-
lipoprotein B and apolipoprotein CII/CIII-B, are not
identical. VLDL apolipoprotein B concentrations in
a control group amount to about 5% of the total
apolipoprotein B, whereas apolipoprotein CII/CIII-B
amounts to about 20%. This discrepancy is probably
caused by co-measurement of chylomicron remnants
and IDL in the described immunoenzymmetric test.
The atherogenic properties of these lipoproteins are
as yet not fully understood.
The possible clinical implication of apolipoprotein
CII/CIII-B measurement is highlighted by our obser-
vation that apolipoprotein CII/CIII-B concentrations
negatively correlate with HDL-cholesterol in male
coronary heart disease patients and are significantly
higher in coronary heart disease patients than in nor-
mal controls. This may reflect a disturbed lipid and
protein exchange between VLDL and HDL in coro-
nary heart disease patients, which results in an accu-
mulation of apolipoprotein B-containing VLDL, and
hence in a pathogenetic influence on the atheroscler-
otic process. In male patients with low HDL-choles-
terol concentrations, it now appears feasible to use
the apolipoprotein CII/CIII-B concentration as an
additional value for a more accurate individual risk
evaluation.
The results reported here are statistically significant,
but their potential clinical importance must be estab-
lished by larger control studies on an appropriate
collective.
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